semaglutide patent expiration us Ozempic, Wegovy and Rybelsus: The patents behind Novo Nordisk's weight-loss drugs Generic SEMAGLUTIDE INN equivalents, pharmaceutical
Description
Published 25 May 2026 Reading time 16 minutes Last reviewed 25 May 2026 TRIUMPH-1 Phase 3 n = 2,339 "The largest weight loss ever observed for a non-surgical obesity treatment" 28.3% Average body weight loss (12 mg, 80 weeks) 30.3% Average weight loss (BMI 35 extension, 104 weeks) 45.3% Of 12 mg participants past the 30% threshold 24.1 cm Average waist circumference reduction at 12 mg The 30-second version What happened: On 21 May 2026, Eli Lilly published topline TRIUMPH-1 Phase 3 results for retatrutide
Association between obesity, high-sensitivity C-reactive protein 2 mg/L, and subclinical atherosclerosis: implications of JUPITER from the Multi-Ethnic Study of Atherosclerosis
Food and Drug Administration (FDA) has approved semaglutide, a glucagon-like peptide receptor agonist (GLP-1RA), to treat type 2 diabetes mellitus (T2DM) and obesity
Auerdem soll es die Blut-Hirn-Schranke leichter berwinden knnen als andere Substanzen aus der Gruppe der GLP-1 Analoga
Treating reproductive-aged women with GLP-1 receptor agonists: cardiometabolic opportunity and reproductive considerations
During periods of significant illness or dehydration, patients should seek medical advice and may need to temporarily interrupt treatment
